Decreased expression of organic cation transporters, Oct1 and Oct2, in brain microvessels and its implication to MPTP-induced dopaminergic toxicity in aged mice

Journal of Cerebral Blood Flow and Metabolism

Volumn 35, Issue 1, 2015, Pages 37-47

  Wu, Kuo Chen ^a   Lu, Ya Hsuan ^a   Peng, Yi Hsuan ^a   Tsai, Ting Fen ^b   Kao, Yu Han ^a   Yang, Hui Ting ^a   Lin, Chun Jung ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

blood brain barrier; MPTP; organic cation transporters

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; NEUROTOXIN; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; TYROSINE 3 MONOOXYGENASE; 1 METHYL 4 PHENYLPYRIDINIUM; DOPAMINE; OCTAMER TRANSCRIPTION FACTOR 1; ORGANIC CATION TRANSPORTER; POU2F1 PROTEIN, MOUSE; SLC22A2 PROTEIN, MOUSE;

AGED; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN CORTEX; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE INACTIVATION; IN VIVO STUDY; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA; ANIMAL; BRAIN; C57BL MOUSE; CORPUS STRIATUM; DOG; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; INTOXICATION; INTRAPERITONEAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; MDCK CELL LINE; METABOLISM; MICRODIALYSIS; MICROVASCULATURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULARIZATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; AGING; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CORPUS STRIATUM; DOGS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; INJECTIONS, INTRAPERITONEAL; MADIN DARBY CANINE KIDNEY CELLS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRODIALYSIS; MICROVESSELS; MPTP POISONING; OCTAMER TRANSCRIPTION FACTOR-1; ORGANIC CATION TRANSPORT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION;

EID: 84920649577     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2014.162     Document Type: Article

References (38)

1. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007; 24:1227-1251.
2. + in rat brain endothelial cells. Life Sci 2007; 81:664-672.
3. Taubert D, Grimberg G, Stenzel W, Schomig E. Identification of the endogenous key substrates of the human organic cation transporter OCT2 and their implication in function of dopaminergic neurons. PLoS ONE 2007; 2:e385.
4. Lin CJ, Tai Y, Huang MT, Tsai YF, Hsu HJ, Tzen KY et al. Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTPinduced dopaminergic toxicity in rodents. J Neurochem 2010; 114:717-727.
5. Dickens D, Owen A, Alfirevic A, Giannoudis A, Davies A, Weksler B et al. Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharmacol 2012; 83:805-814.
6. Friedrich A, George RL, Bridges CC, Prasad PD, Ganapathy V. Transport of choline and its relationship to the expression of the organic cation transporters in a rat brain microvessel endothelial cell line (RBE4). Biochim Biophys Acta 2001; 1512: 299-307.
7. Okura T, Hattori A, Takano Y, Sato T, Hammarlund-Udenaes M, Terasaki T et al. Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab Dispos 2008; 36: 2005-2013.
8. Sung JH, Yu KH, Park JS, Tsuruo T, Kim DD, Shim CK et al. Saturable distribution of tacrine into the striatal extracellular fluid of the rat: evidence of involvement of multiple organic cation transporters in the transport. Drug Metab Dispos 2005; 33: 440-448.
9. Geier EG, Chen EC, Webb A, Papp AC, Yee SW, Sadee W et al. Profiling solute carrier transporters in the human blood-brain barrier. Clin Pharmacol Ther 2013; 94:636-639.
10. André P, Saubaméa B, Cochois-Guégan V, Marie-Claire C, Cattelotte J, Smirnova M et al. Transport of biogenic amine neurotransmetters at the mouse blood-retina and blood-brain barriers by uptake 1 and uptake2. J Cerebral Blood Flow Metab 2012; 32:1989-2001.
11. Wu KC, Pan HJ, Yin HS, Chen MR, Lu SC, Lin CJ. Change in P-glycoprotein and caveolin protein expression in brain striatum capillaries in New Zealand obese mice with type 2 diabetes. Life Sci 2009; 85:775-781.
12. Chang TT, Shyu MK, Huang MC, Hsu CC, Yeh SY, Chen MR et al. Hypoxia-mediated down-regulation of OCTN2 and PPARα expression in human placentas and in BeWo cells. Mol Pharm 2011; 7:117-125.
13. Zhang W, Wang T, Qin L, Gao HM, Wilson B, Ali SF et al. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J 2004; 18:589-591.
14. Yeh SY, Pan HJ, Lin CC, Kao YH, Chen YH, Lin CJ. Hyperglycemia-induced downregulation of renal P-glycoprotein expression. Eur J Pharmacol 2012; 690:42-50.
15. Hindle JV. Ageing, neurodegeneration and Parkinson's disease. Age Aging 2010; 39:156-161.
16. Rudow G, O'Brien R, Savonenko AV, Resnick SM, Zonderman AB, Pletnikova O et al. Morphometry of the human substantia nigra in ageing and Parkinson's disease. Acta Neuropathol 2008; 115:461-470.
17. Kubis N, Faucheux BA, Ransmayr G, Damier P, Duyckaerts C, Henin D et al. Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 2000; 123:366-373.
18. Schumm S, Sebban C, Cohen-salmon C, Callebert J, Launay JM, Golmard JL et al. Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 2012; 122:1032-1036.
19. Sugama S, Yang L, Cho BP, De Giorgio LA, Lorenzl S, Albers DS et al. Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 2003; 964:288-294.
20. Ali SF, David SN, Newport GD, Cadet JL, Slikker W, Jr. MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse 1994; 18:27-34.
21. Javitch JA, D'Amato RJ, Stritimatter SM, Snyder SH. Parkinism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 1985; 82:2173-2177.
22. Cui M, Aras R, Christian WV, Rappold PM, Hatwar M, Panza J et al. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrastriatal dopaminergic pathway. Proc Natl Acad Sci USA 2009; 106:8043-8048.
23. Salvatore MF, Apparsundaram S, Gerhardt GA. Decreased plasma membrane expression of striatal dopamine transporter in aging. Neurobiol Aging 2003; 24: 1147-1154.
24. Sriram K, Pai KS, Boyd MR, Ravindranath V. Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice. Brain Res 1997; 749: 44-52.
25. Le Doux MS. Tetrahydroisoquinolines and Parkinson's disease. In: Pfeiffer RF, Wszolek ZK, Ebadi M (eds), Parkinson's Disease. 2nd edn. CRC Press: Boca Raton, FL, 2012, pp 91-108.
26. Kotake Y, Tasaki Y, Makino Y, Ohta S, Hirobe M. 1-benzyl-1,2,3,4-tetrahydroisoquinoline as a Parkinsonism-inducing agent: A novel endogenous amine in mouse brain and Parkinsonian CSF. J Neurochem 1995; 65:2633-2638.
27. Maruyama W, Abe T, Toligi H, Dostert P, Naoi M. A dopaminergic neurotoxin, (R)- N-methylsalsolinol, increases in Parkinsonian cerebraospinal fluid. Ann Neurol 1996; 40:119-122.
28. Antkiewicz-Michaluk L, Krygowska-Wajs A, Szezudlik A, Romanska I, Vetulani J. Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: Advantage of a new high-performance liquid chromatography methodology. Biol Psychiatry 1997; 42:514-518.
29. Hamre K, Tharp R, Poon K, Xiong X, Smeyne RJ. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res 1999; 828:91-103.
30. Jakowee MW, Petzinger GM. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates. Comp Med 2004; 54:497-513.
31. Riachi NJ, Harik SI. Strain differences in systemic 1-methyl-4-phyenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice correlate best with monoamine oxidase activity at the blood-brain barrier. Life Sci 1988; 42:2359-2363.
32. Nicotra A, Piecucci F, Parvez H. Senatori. Monoamine oxidase expression during development and aging. Neurotoxicology 2004; 25:155-165.
33. Irwin I, De Lanney LE, Langston JW. MPTP and aging: studies in C57BL/6 mouse. Adv Neurol 1993; 60:197-206.
34. Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK. Correlation between the neostriatal content of the 1-methyl-4-phynylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J Pharmacol Exp Ther 1991; 257:691-697.
35. Walsh S, Wagner G. Age-dependent effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): correlation with monoamine oxidase-B. Synapse 1989; 3: 308-314.
36. Jossan SS, Sakurai E, Oreland L. MPTP toxicity in relation to age, dopamine uptake and MAO-B activity in two rodent species. Pharmacol Toxicol 1989; 64:314-318.
37. Andersen JK, Frim DM, Isacson O, Beal MF, Breakefield XO. Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Brain Res 1994; 656:108-114.
38. +)-induced nigro-striatal dopaminergic cell loss between C57BL/6 and BALB/c mice is not related to the difference of monoamine oxidase-B (MAO-B). Exp Toxicol Pathol 2013; 65:153-158.